Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
54 studies found for:    anaplastic large cell lymphoma | Open Studies
Show Display Options
Rank Status Study
1 Not yet recruiting Ceritinib With Brentuximab Vedotin in Treating Patients With ALK-Positive Anaplastic Large Cell Lymphoma
Conditions: Anaplastic Large Cell Lymphoma, ALK-Positive;   Systemic Anaplastic Large Cell Lymphoma
Interventions: Drug: Brentuximab Vedotin;   Drug: Ceritinib;   Other: Laboratory Biomarker Analysis;   Other: Pharmacological Study
2 Recruiting Brentuximab Vedotin (Recombinant) for IV Infusion - Special Drug Use Surveillance (All-case Surveillance) "Relapsed or Refractory CD30+ Hodgkin's Lymphoma or Anaplastic Large Cell Lymphoma"
Condition: Relapsed or Refractory CD30+ Hodgkin's Lymphoma or Anaplastic Large Cell Lymphoma
Intervention: Drug: Brentuximab vedotin (recombinant)
3 Recruiting Crizotinib and Combination Chemotherapy in Treating Younger Patients With Relapsed or Refractory Solid Tumors or Anaplastic Large Cell Lymphoma
Conditions: Recurrent Childhood Anaplastic Large Cell Lymphoma;   Recurrent Neuroblastoma;   Unspecified Childhood Solid Tumor, Protocol Specific
Interventions: Drug: crizotinib;   Drug: cyclophosphamide;   Drug: topotecan hydrochloride;   Drug: vincristine sulfate;   Drug: dexrazoxane hydrochloride;   Drug: doxorubicin hydrochloride;   Other: pharmacological study;   Other: laboratory biomarker analysis;   Other: pharmacogenomic studies;   Other: questionnaire administration
4 Recruiting Brentuximab Vedotin in Chinese Participants With Relapsed/Refractory CD30-Positive Hodgkin Lymphoma (HL) or Systemic Anaplastic Large Cell Lymphoma (sALCL)
Conditions: Hodgkin Disease;   Lymphoma, Large-Cell, Anaplastic
Intervention: Drug: Brentuximab Vedotin
5 Recruiting Study of the Biological Mechanisms Associated With the Immunogenicity in Anaplastic Large Cell Lymphoma ( ALCL ) ALK +
Condition: ALCL
Intervention: Other: Blood sample
6 Recruiting AT13387 in Treating Patients With Relapsed or Refractory Anaplastic Large Cell Lymphoma, Mantle Cell Lymphoma, or Diffuse Large B-cell Lymphoma
Conditions: ALK Positive;   BCL6 Positive;   Recurrent Anaplastic Large Cell Lymphoma;   Recurrent Diffuse Large B-Cell Lymphoma;   Recurrent Mantle Cell Lymphoma;   Refractory Anaplastic Large Cell Lymphoma;   Refractory Diffuse Large B-Cell Lymphoma;   Refractory Mantle Cell Lymphoma
Interventions: Other: Laboratory Biomarker Analysis;   Drug: Onalespib
7 Recruiting Brentuximab Vedotin and Imatinib in Patients With Relapsed or Refractory ALK+ ALCL
Condition: ALK+ Anaplastic Large Cell Lymphoma
Interventions: Drug: Brentuximab vedotin;   Drug: Imatinib
8 Recruiting Brentuximab Vedotin for Relapsed/Refractory CD30-positive Non-Hodgkin Lymphomas
Condition: Non-Hodgkin Lymphoma
Intervention: Drug: Brentuximab vedotin
9 Recruiting Brentuximab Vedotin in High-Risk CD30+ Lymphoma Post Allogeneic Stem Cell Transplantation (AlloSCT)
Condition: Lymphoma
Intervention: Drug: Brentuximab Vedotin
10 Recruiting Pilot Study of Crizotinib in Relapsed ALK+ Lymphomas
Condition: Anaplastic Large Cell Lymphoma, ALK-Positive
Intervention: Drug: crizotinib
11 Available A Treatment-Option Protocol to Provide Brentuximab Vedotin to Eligible Patients Completing Studies SGN35-005 or C25001
Conditions: Disease, Hodgkin;   Lymphoma, Large-Cell, Anaplastic;   Lymphoma, Non-Hodgkin;   Lymphoma, T-Cell, Cutaneous
Intervention: Drug: brentuximab vedotin
12 Recruiting Risk Stratification of Nodal PTCL
Conditions: Peripheral T-Cell Lymphoma, Not Otherwise Specified;   Angioimmunoblastic T-cell Lymphoma;   Anaplastic Large Cell Lymphoma, ALK-negative
Intervention:
13 Recruiting CAR T Cells Targeting CD30 Positive Lymphomas (4SCAR30273)
Condition: Lymphomas
Intervention: Genetic: Anti-CD30 CAR T cells
14 Recruiting Phase I Study of LDK378 in Pediatric, Malignancies With a Genetic Alteration in Anaplastic Lymphoma Kinase (ALK)
Condition: Anaplastic Lymphoma Kinase (ALK)
Intervention: Drug: LDK378
15 Recruiting T Cells Expressing a Fully-Human Anti-CD30 Chimeric Antigen Receptor for Treating CD30-Expressing Lymphomas
Conditions: Lymphoma, Large-Cell, Anaplasitc;   Hodgkin Disease;   Lymphoma, Hodgkins;   Enteropathy-Associated T-Cell Lymphoma;   Lymphoma, Extranodal NK-T-Cell
Interventions: Biological: Anti-CD30-CAR T cells;   Drug: Cyclophosphamide;   Drug: Fludarabine
16 Recruiting Dose-Adjusted EPOCH Chemotherapy and Rituximab (CD20+) in Previously Untreated Aggressive Non-Hodgkin's Lymphoma
Conditions: Diffuse Large B-Cell Lymphoma (DLBCL);   Primary Mediastinal Large B-cell Lymphoma;   Burkitt Lymphoma;   Anaplastic Large-Cell Lymphoma;   Gray Zone Lymphoma
Interventions: Drug: EPOCH;   Biological: Rituximab
17 Recruiting CHOP vs GEM-P in 1st Line Treatment of T-cell Lymphoma, Multicentre Phase II Study
Conditions: Peripheral T-cell Lymphoma NOS;   Anaplastic Large Cell Lymphoma, ALK-Negative;   Angioimmunoblastic T-cell Lymphoma;   Hepatosplenic Gamma/ Delta T-cell Lymphoma
Interventions: Drug: Cyclophosphamide;   Drug: Gemcitabine;   Drug: Doxorubicin;   Drug: Vincristine;   Drug: Prednisolone;   Drug: methylprednisolone;   Drug: Cisplatin
18 Recruiting Romidepsin in Combination With CHOEP as First Line Treatment Before Hematopoietic Stem Cell Transplantation in Young Patients With Nodal Peripheral T-cell Lymphomas: a Phase I-II Study
Conditions: Peripheral T-cell Lymphomas (PTCL);   PTCL-NOS;   Angioimmunoblastic T-cell Lymphoma (AITL);   ALK- Anaplastic Large Cell Lymphoma (ALCL)
Interventions: Drug: Ro-CHOEP-21 (PHASE I);   Drug: Ro-CHOEP-21 (PHASE II)
19 Recruiting CREATE: Cross-tumoral Phase 2 With Crizotinib
Conditions: Locally Advanced and/or Metastatic Anaplastic Large Cell Lymphoma;   Locally Advanced and/or Metastatic Inflammatory Myofibroblastic Tumor;   Locally Advanced and/or Metastatic Papillary Renal Cell Carcinoma Type 1;   Locally Advanced and/or Metastatic Alveolar Soft Part Sarcoma;   Locally Advanced and/or Metastatic Clear Cell Sarcoma;   Locally Advanced and/or Metastatic Alveolar Rhabdomyosarcoma
Intervention: Drug: Crizotinib (PF-02341066)
20 Recruiting Nivolumab in Treating Patients With Relapsed or Refractory Peripheral T-cell Lymphoma
Conditions: Blastic Plasmacytoid Dendritic Cell Neoplasm;   Hepatosplenic T-Cell Lymphoma;   HTLV-1 Infection;   NK-Cell Lymphoma, Unclassifiable;   Primary Systemic Anaplastic Large Cell Lymphoma, ALK-Negative;   Recurrent Adult T-Cell Leukemia/Lymphoma;   Recurrent Anaplastic Large Cell Lymphoma;   Recurrent Angioimmunoblastic T-cell Lymphoma;   Recurrent Enteropathy-Associated T-Cell Lymphoma;   Recurrent Mycosis Fungoides;   Refractory Adult T-Cell Leukemia/Lymphoma;   Refractory Anaplastic Large Cell Lymphoma;   Refractory Angioimmunoblastic T-cell Lymphoma;   Refractory Enteropathy-Associated T-Cell Lymphoma;   Refractory Mycosis Fungoides;   Refractory Nasal Type Extranodal NK/T-Cell Lymphoma;   Refractory Peripheral T-Cell Lymphoma, Not Otherwise Specified
Interventions: Other: Laboratory Biomarker Analysis;   Biological: Nivolumab

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.